Skip to content
DataLookout
Menu

Daiichi Sankyo clinical trial pipeline

Get alerts when Daiichi Sankyo's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

17 trials changed in the last 30 days: 1 stopped, 8 with notable changes, 8 with minor changes only.

  1. Notable: HER3-DXd · Locally Advanced or Metastatic Solid Tumors Primary completion pushed from Sep 1, 2027 to Nov 19, 2030 Daiichi SankyoPhase 2 NCT06172478
  2. Notable: Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Recruitment opened Daiichi SankyoPhase 3 NCT07474649
  3. Notable: DB-Guide · T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Start date pushed from Sep 18, 2026 to Nov 4, 2026 Daiichi SankyoPhase 3 NCT07683754
  4. Notable: Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) Start date pushed from Oct 1, 2026 to Mar 31, 2027 Daiichi SankyoPhase 3 NCT07791732
  5. Minor: Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) Study completion pushed from Aug 31, 2027 to Jun 19, 2029 Daiichi SankyoPhase 2 NCT04703192
  6. Stopped: Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment Trial status changed: Recruiting → Withdrawn Daiichi SankyoNot specified NCT04635111
  7. Notable: DO-01 · Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) Primary endpoint(s) modified Daiichi SankyoPhase 3 NCT06819007
  8. Notable: DS-3939a · Solid Tumors Recruitment opened Daiichi SankyoPhase 1/2 NCT07739966
  9. Notable: Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting Primary completion moved earlier from Mar 23, 2032 to Feb 26, 2030 Daiichi SankyoPhase 3 NCT07022483
  10. Notable: Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) Primary and study completion dates pushed to Feb 17, 2028 Daiichi SankyoPhase 3 NCT06174987
  11. Minor: Ifinatamab Deruxtecan · Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) Trial sites expanded: 132 → 168 locations Daiichi SankyoPhase 3 NCT06644781
  12. Minor: Raludotatug Deruxtecan (R-DXd) · Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Trial sites expanded: 164 → 167 locations Daiichi SankyoPhase 2/3 NCT06161025
  13. Minor: Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) Trial sites expanded: 19 → 29 locations Daiichi SankyoPhase 1 NCT07244341
  14. Minor: DS-1103a Combination Therapy · Advanced Solid Tumors Trial sites expanded: 11 → 15 locations Daiichi SankyoPhase 1 NCT05765851
  15. Minor: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib · Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer Study completion pushed from Apr 30, 2027 to Dec 14, 2027 Daiichi SankyoPhase 1 NCT04676477
  16. Minor: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer Primary completion date changed from estimate of Mar 31, 2026 to Dec 1, 2025 Daiichi SankyoPhase 1 NCT03260491
  17. Minor: DESTINY-Lung06 · Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer Trial sites expanded: 242 → 246 locations Daiichi SankyoPhase 3 NCT06899126
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-22 NCT07890714 A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] Phase 1/2 Recruiting

Active trials by phase

Phase 1
16
Phase 1/2
10
Phase 2
6
Phase 2/3
2
Phase 3
18
Not charted: 5 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 25

Get alerts when Daiichi Sankyo's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free